Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial
Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2024
DOI: 10.1089/jamp.2023.0043 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2024. Verfasst von Farhad Abolhasan Choobdar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ali-Asghar Children's Hospital, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. Hauptthemen laut MEDLINE: Albuterol, Nebulizers and Vaporizers, Transient Tachypnea of the Newborn. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
To evaluate the safety and efficacy of 2.5 and 1.25 mg nebulized salbutamol on Transient Tachypnea of the Newborn (TTN) compared with placebo.
Methods
We conducted a triple-blind, phase II/III parallel randomized controlled trial in two university-affiliated hospitals with neonatal intensive care units. Newborns with a confirmed diagnosis of TTN, with gestational age >35 weeks and gestational weight >2 kg were included. Cases of asphyxia, meconium aspiration syndrome, and persistent pulmonary hypertension were excluded. Ninety eligible patients were randomly allocated in three intervention groups (2.5 mg salbutamol, 1.25 mg salbutamol, and placebo), and a single-dose nebulized product was prescribed 6 hours after the birth. Safety outcomes included postintervention tachycardia, hyperglycemia, hypokalemia, and changes in blood pressure. To evaluate the efficacy, the duration of postintervention tachypnea, TTN clinical score, and clinical and paraclinical respiratory indices were assessed. Parents, Outcome assessors, and data analyzer were blind to the intervention.
Results
There was no adverse reaction, including tachycardia, hypokalemia, and jitteriness. Both groups of salbutamol recipients showed significant improvement regarding respiratory rate, TTN clinical score, and oxygenation indices compared with the placebo ( p -values
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ali-Asghar Children's Hospital, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
- Firooz Abadi Hospital, and School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
- Shahid Akbar Abadi Clinical Research Development Unit (ShACRDU), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
- Department of Pediatric, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran.
- School of Public Health, Iran University of Medical Sciences (IUMS), Tehran, Iran.
- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
ORCID-Profile: Rezvan Ashkanipour
Zitieren
APA
Choobdar, F. A., Vahedi, Z., Mazouri, A., Torkaman, M., Khosravi, N., Khalesi, N., Soltani, Z., Mohazzab, A., & Ashkanipour, R. (2024). Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery. https://doi.org/10.1089/jamp.2023.0043
Vancouver
Choobdar FA, Vahedi Z, Mazouri A, Torkaman M, Khosravi N, Khalesi N, et al. Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2024. doi:10.1089/jamp.2023.0043
BibTeX
@article{Choobdar2024,
author = {Choobdar, Farhad Abolhasan and Vahedi, Zahra and Mazouri, Ali and Torkaman, Mohammad and Khosravi, Nastaran and Khalesi, Nasrin and Soltani, Zahra and Mohazzab, Arash and Ashkanipour, Rezvan},
title = {Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial},
journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
year = {2024},
doi = {10.1089/jamp.2023.0043}
}
EUVIMED